• Pyritinol is a substance belonging to the group of nootropics.
  • Pyritinol improves the pathologically reduced metabolism in the brain by increasing uptake and utilization of glucose, nucleic acid metabolism, cortical acetylcholine release and cholinergic transmission. This results in improved blood fluidity and increases cerebral microcirculation in regions with deficient blood flows in the brain.

Each 5ml of Encefal® contains:

  • Pyritinol HCl               100 mg      (equivalent to 80.5mg of pyritinol)
  • Symptoms of cerebral insufficiency due to metabolic and circulatory disorders in the brain.
  • Conditions after cranio-cerebral trauma.   
  • Hypersensitivity to pyritinol.
  • Severe liver disorders.
  • Severe kidney disorders.
  • Severe changes in blood count.
  • Acute autoimmune diseases (for example lupus erythematosus, myasthenia, pemphigus) 
  • Penicillamine, sulfasalazine, gold preparations or levamisol, concomitant administration of pyritinol can potentiate the side effects of these substances.
  • Pyritinol passes the placental barrier.
  • Only small amounts of pyritinol are excreted into breast milk.
  • Encefal® should only be used during pregnancy and lactation after carefully assesing the benefit/risk ratio by your doctor.
  • Allergic reactions (skin rash, nausea, diarrhea, fever, chills, itching)
  • Decrease in number of white blood cells.
  • Liver function disorders, accumulation of bile, hepatitis, cholestatic hepatitis, jaundice.
  • Decreased appetite.
  • Muscle and joint pain.
  • Diffeculties in breathing.
  • Sleep disturbances, increased excitability, headache, dizziness, taste disturbances and numbness in skin.
  • Nephrotic syndrome, proteinuria or haematuria.
  • Encefal® should be taken with caution in patients with rheumatoid arthritis, and clinical check-ups and laboratory tests should be performed regularly. Due to the increased sensetivity to pyritinol, the adverse reactions are more frequent than in other patients.

¤ The dose depends on both the degree of the severity of the disease and the patient’s response to the treatment.

  • Adults: 10 ml 3 times daily.
  • Children: (2.5 - 15 ml) one to three times daily.
  • In chronic diseases, therapeutic success is observed after 6 - 12 weeks.

¤ If you experience sleep disturbances, do not take this medicine in the evening or before bed.

¤ If you forget to take Encefal®, do not take a double dose but take the normal dose the following day.

  • Bottle of 100 ml oral suspension.
  • Shake the bottle before use.
  • Store at temperature below 25° C.